{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:23:23Z","timestamp":1786991003146,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81960035"],"award-info":[{"award-number":["81960035"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["2023LNS17475"],"award-info":[{"award-number":["2023LNS17475"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.intimp.2026.116170","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T11:02:20Z","timestamp":1768820540000},"page":"116170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Identification of Siglec-15 as a novel target for CAR-T cell therapy in acute myeloid leukemia"],"prefix":"10.1016","volume":"172","author":[{"given":"Haidong","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongkai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.intimp.2026.116170_bb0005","article-title":"Selective translation of nuclear mitochondrial respiratory proteins reprograms succinate metabolism in AML development and chemoresistance","volume":"31","author":"Guoqiang","year":"2024","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.intimp.2026.116170_bb0010","article-title":"The dual role of autophagy in acute myeloid leukemia","volume":"15","author":"Wonhyoung","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116170_bb0015","article-title":"Preclinical evaluation of CD64 as a potential target for CAR-T-cell therapy for acute myeloid Leukemia","volume":"45","author":"Xiaolei","year":"2021","journal-title":"J. Immunother."},{"issue":"9","key":"10.1016\/j.intimp.2026.116170_bb0020","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116170_bb0025","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Mark","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2026.116170_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15051617","article-title":"Molecularly targeted therapy in acute myeloid Leukemia: current treatment landscape and mechanisms of response and resistance","volume":"15","author":"Lachowiez","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2026.116170_bb0035","doi-asserted-by":"crossref","unstructured":"A. Desmond O, A. Christian K, A. Du-Bois, A. Ernest A, B. Prince A, B. Dan O M, K. Foster, Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy, Biomed. Pharmacother. 97(0) (2017).","DOI":"10.1016\/j.biopha.2017.10.100"},{"issue":"24","key":"10.1016\/j.intimp.2026.116170_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246246","article-title":"Immunotherapy as a turning point in the treatment of acute myeloid Leukemia","volume":"13","author":"Aureli","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.intimp.2026.116170_bb0045","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116170_bb0050","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"In\u00e9s","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2026.116170_bb0055","article-title":"CD123 a therapeutic target for acute myeloid Leukemia and Blastic Plasmocytoid dendritic neoplasm","volume":"24","author":"Elvira","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.intimp.2026.116170_bb0060","article-title":"CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia","volume":"29","author":"K. S S, R. M, S. O, K. M, A. V, M. J J D, S. J, S. D, P. D L, C. M, J. C H, G. S","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.intimp.2026.116170_bb0065","article-title":"Unveiling the potential of CLL-1: a promising target for AML therapy","volume":"13","author":"Hamed","year":"2025","journal-title":"Biomark. Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.116170_bb0070","article-title":"Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia","volume":"103","author":"Xiangyu","year":"2024","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116170_bb0075","article-title":"Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia, blood","volume":"12","author":"Nawid","year":"2022","journal-title":"Cancer J."},{"issue":"6","key":"10.1016\/j.intimp.2026.116170_bb0080","article-title":"Acute myeloid leukemia chimeric antigen receptor T-cell immunotherapy: how far up the road have we traveled?","volume":"9","author":"Sarah K","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"7","key":"10.1016\/j.intimp.2026.116170_bb0085","article-title":"T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments","volume":"35","author":"Naval","year":"2021","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.intimp.2026.116170_bb0090","article-title":"Siglecs in the immune system","volume":"103","author":"C. P R, V. A","year":"2001","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.intimp.2026.116170_bb0095","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"J","year":"2017","journal-title":"Nat. Med."},{"issue":"19","key":"10.1016\/j.intimp.2026.116170_bb0100","article-title":"Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia","volume":"138","author":"Hardikkumar","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116170_bb0105","article-title":"Siglec15 in blood system diseases: from bench to bedside","volume":"15","author":"Yujia","year":"2024","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2026.116170_bb0110","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Jun","year":"2019","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.intimp.2026.116170_bb0115","article-title":"Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia","volume":"3","author":"P. Claire E, D. Jodi, R. Jennifer L, F. Jairo A, Z. Chengjing, E. Alyssa N, A. Hasan, I. Ona, G.-F. Gloria, P. Sunita I, A. Ahmed, D. Deborah, C. Sharon M, R. Sarwish, L. Solomon, L. Linda N, H. Curtis J, P. Christopher C","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"3","key":"10.1016\/j.intimp.2026.116170_bb0120","first-page":"680","article-title":"Siglec-15 as an emerging target for next-generation Cancer immunotherapy, clinical cancer research\u202f: an official journal of the American association for","volume":"27","author":"Sun","year":"2021","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.intimp.2026.116170_bb0125","article-title":"Sialic acid-binding immunoglobulin-like lectin (Sigelac)-15 is a rapidly internalised cell-surface antigen expressed by acute myeloid leukaemia cells","volume":"193","author":"Huan","year":"2021","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.intimp.2026.116170_bb0130","article-title":"Cytohesin-4\/ARF6 facilitates the progression of acute myeloid leukemia through activating PIK3R5\/PI3K\/AKT pathway","volume":"28","author":"Xiao-Fen","year":"2025","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.intimp.2026.116170_bb0135","article-title":"C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial","volume":"15","author":"Shiyu","year":"2024","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.intimp.2026.116170_bb0140","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic Leukemia","volume":"378","author":"H","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.intimp.2026.116170_bb0145","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116170_bb0150","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/B978-0-12-385493-3.00010-3","article-title":"Immunophenotypic pattern of myeloid populations by flow cytometry analysis","volume":"103","author":"Gorczyca","year":"2011","journal-title":"Methods Cell Biol."},{"issue":"2","key":"10.1016\/j.intimp.2026.116170_bb0155","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"Courtney D","year":"2019","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.intimp.2026.116170_bb0160","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic Leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116170_bb0165","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nm.4441","article-title":"CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116170_bb0170","article-title":"Loop33\u00d7123 CAR-T targeting CD33 and CD123 against immune escape in acute myeloid leukemia","volume":"74","author":"Haotian","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.intimp.2026.116170_bb0175","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1172\/JCI87366","article-title":"Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.intimp.2026.116170_bb0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-019-0741-6","article-title":"Haploidentical CD19\/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation","volume":"12","author":"Jia","year":"2019","journal-title":"J. Hematol. Oncol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:55:41Z","timestamp":1776164141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926000135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"alternative-id":["S1567576926000135"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116170","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of Siglec-15 as a novel target for CAR-T cell therapy in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116170"}}